AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 26, 2021 GMT

SAN DIEGO--(BUSINESS WIRE)--May 26, 2021--

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following investor conferences:

Jefferies 2021 Virtual Healthcare Conference
Fireside Chat Presentation: Wednesday, June 2, 2021 at 1:30 p.m. Eastern Time

Goldman Sachs 42 nd Annual Global Healthcare Conference
Fireside Chat Presentation: Tuesday, June 8, 2021 at 2:10 p.m. Eastern Time

These conferences will be held virtually. Live webcasts of the presentations will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website for approximately one month following each presentation.

ADVERTISEMENT

About Acadia Pharmaceuticals

Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia-pharm.com and follow us on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20210526005191/en/

CONTACT: Media Contact:

Acadia Pharmaceuticals Inc.

Eric Endicott

(858) 914-7161

ADVERTISEMENT

media@acadia-pharm.comInvestor Contact:

Acadia Pharmaceuticals Inc.

Mark Johnson, CFA

(858) 261-2771

ir@acadia-pharm.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: MENTAL HEALTH RESEARCH FINANCE CLINICAL TRIALS PROFESSIONAL SERVICES BIOTECHNOLOGY HEALTH PHARMACEUTICAL SCIENCE

SOURCE: Acadia Pharmaceuticals Inc.

Copyright Business Wire 2021.

PUB: 05/26/2021 09:00 AM/DISC: 05/26/2021 09:03 AM

http://www.businesswire.com/news/home/20210526005191/en